格隆汇12月10日丨福安药业(300194.SZ)公布，全资子公司福安药业集团湖北人民制药有限公司于近日 收到国家药品监督管理局签发的药品注册证书，药品名称：注射用硫酸艾沙康唑。注射用硫酸艾沙康唑 适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性毛霉病。根据国家药品监督管理局数据查询信息 平台显示，截止目前，该药品共有11家企业（含人民制药）通过一致性评价或视同通过一致性评价。 ...

福安药业12月10日公告，公司全资子公司福安药业集团湖北人民制药有限公司收到国家药品监督管理局 签发的药品注册证书，药品名称为注射用硫酸艾沙康唑，注册分类为化药4类，规格为0.2g。该药品适 用于治疗成人患者侵袭性曲霉病和侵袭性毛霉病。截至目前，共有11家企业（含人民制药）通过一致性 评价或视同通过一致性评价。药品注册证书的获得将进一步丰富子公司产品线，提升市场竞争力，但受 行业政策、市场环境变化等因素影响，产品的生产、销售情况以及对公司业绩的具体影响存在不确定 性。 ...

人民财讯12月10日电，福安药业（300194）12月10日公告，公司全资子公司福安药业集团湖北人民制药 有限公司于近日收到国家药品监督管理局签发的注射用硫酸艾沙康唑药品注册证书。注射用硫酸艾沙康 唑适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性毛霉病。 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-044 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团湖北人民制药有限公司（以下简称"人民制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 注射用硫酸艾 沙康唑 | 化药 4 | 类 | 0.2g | 人民制药 | 国药准字 | 经审查，本品符合药品注册的有关要 | | --- | --- | --- | --- | --- | --- | --- | | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 H20256127 | 审批结论 求，批准注册，发给药品注册证书。 | 注射用硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性 毛霉病。根据国家药品监督管理局数据查询信息平台显示，截止目前，该药品共 有 11 家企业（含人民制药）通过一致性评价或视同通过一致性评价。 上述药品注册证 ...

Group 1 - The core announcement from Fu'an Pharmaceutical states that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security will release a notification regarding the drug "Palaniv" injection [2]

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Group 1 - The core point of the article is that Fu'an Pharmaceutical (300194.SZ) announced that its subsidiary's product, Palivizumab injection, has been included in the National Medical Insurance Drug List as per the notice issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 2 - The inclusion of Palivizumab injection in the National Medical Insurance Drug List is expected to enhance the product's market accessibility and potentially increase sales [1] - This development reflects the government's ongoing efforts to expand the coverage of essential medications under the national insurance scheme [1] - The announcement may positively impact the company's financial performance and investor sentiment in the pharmaceutical sector [1]

Core Viewpoint - Fuan Pharmaceutical's product, Palivizumab injection, has been included in the National Medical Insurance Drug List, which is expected to enhance the company's market position and revenue potential [1] Group 1 - Fuan Pharmaceutical announced that its subsidiary's product, Palivizumab injection, has been added to the National Medical Insurance Drug List [1] - The inclusion in the drug list is part of the notification issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1]

Core Viewpoint - The inclusion of Fuan Pharmaceutical's product, Palivizumab injection, in the National Medical Insurance Drug List (2025) is expected to positively impact sales, although the exact effect on future performance remains uncertain due to potential changes in industry policies and market conditions [1] Group 1 - Fuan Pharmaceutical announced that its subsidiary's product, Palivizumab injection, has been newly included in the National Medical Insurance Drug List [1] - The updated National Medical Insurance Drug List will officially take effect on January 1, 2026 [1] - The inclusion in the drug list is anticipated to have a positive effect on the sales of the related product [1] Group 2 - The future sales performance of the drug is subject to uncertainties influenced by changes in pharmaceutical industry policies and market environment [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on December 8 that its subsidiary's product, Peramivir Injection, has been newly included in the National Medical Insurance Drug List for 2025, which is used for the treatment of influenza A or B [1] Company Summary - Fu'an Pharmaceutical's subsidiary has successfully added Peramivir Injection to the National Medical Insurance Drug List for 2025 [1] - The inclusion of this product is significant as it expands the treatment options available for influenza A and B [1] Industry Summary - The addition of Peramivir Injection to the National Medical Insurance Drug List indicates a positive trend in the pharmaceutical industry regarding the accessibility of antiviral treatments [1] - This move may enhance the competitive landscape for companies involved in the production of antiviral medications [1]